Rat study finds limited melatonin benefit in hyperprolactinemia: full analysis
A newly published study in Frontiers in Veterinary Science suggests melatonin may not do as much as hoped to protect digestive and hepatic tissues in hyperprolactinemia. In a male rat model, investigators found that domperidone-induced hyperprolactinemia produced structural changes in the stomach, duodenum, and liver, while exogenous melatonin had only limited effects, mainly on body weight and one duodenal histochemical parameter rather than on the broader pattern of organ injury. (frontiersin.org)
The work builds on a familiar endocrine story with a less familiar tissue focus. Hyperprolactinemia is usually discussed in relation to reproductive dysfunction, but the authors argue that its systemic effects likely extend further. Their protocol used 24 adult male rats split into control, hyperprolactinemia, and hyperprolactinemia-plus-melatonin groups. Hyperprolactinemia was induced with daily subcutaneous domperidone at 4 mg/kg for 60 days, while melatonin was given subcutaneously at 200 μg per 100 g body weight over the same period. The same research line had previously reported melatonin-related protection in testicular tissue under domperidone-induced hyperprolactinemia, making the weaker signal in gastrointestinal and liver tissues notable. (frontiersin.org)
On the pathology side, the study found that hyperprolactinemic rats had increased body weight and gastric lumen dilation, along with duodenal changes including increased villus and microvillus height. In the liver, the authors documented microsteatosis, fewer Kupffer cells, and a higher number of binucleated hepatocytes in hyperprolactinemic animals. PCNA immunolabeling rose in the liver and, to a lesser extent, in the stomach, while decreasing in the duodenum in the hyperprolactinemic groups. Melatonin did not consistently reverse these findings. In fact, the Hyper+MEL group had significantly more binucleated hepatocytes than either controls or untreated hyperprolactinemic rats, even as body weight tracked closer to control values. (frontiersin.org)
That mixed result matters because melatonin has a plausible biologic rationale in digestive and hepatic tissues. Prior literature describes melatonin production and signaling within the gastrointestinal tract, with reported effects on motility, mucosal physiology, ulcer biology, and oxidative stress responses. Other preclinical liver studies have suggested antifibrotic or protective effects in specific injury models. But those broader mechanistic expectations didn’t translate into robust protection in this hyperprolactinemia model, at least under the dose, route, and timing used here. (frontiersin.org)
No outside expert commentary tied specifically to this paper was readily available in the sources reviewed, but the study’s own discussion underscores why the result is important: it highlights how strongly melatonin responses may depend on context. The authors note that prior animal studies have reported divergent effects on body mass and tissue protection depending on dose, treatment duration, route of administration, and the underlying metabolic state. That’s a familiar issue in translational endocrine pharmacology, and it may explain why melatonin looked more promising in earlier reproductive-tissue work than in this stomach-duodenum-liver analysis. (frontiersin.org)
Why it matters: For veterinarians and veterinary researchers, this is less about immediate clinical use and more about sharpening the evidence base around endocrine comorbidities and adjunctive therapies. The paper reinforces that hyperprolactinemia may have multisystem consequences, including gastrointestinal and hepatic remodeling, and that a compound with theoretical antioxidant and regulatory benefits may still fail to deliver consistent histologic protection. For clinicians, that’s a reminder to be careful when extrapolating from melatonin’s broad reputation to specific disease settings. For researchers, it points to a gap in comparative pathology and translational endocrinology, especially around how prolactin dysregulation affects nonreproductive organs. (frontiersin.org)
What to watch: The next meaningful step will be replication in other species and disease contexts, plus protocol refinement, including alternate dosing, delivery routes, and treatment windows. It would also be useful to see whether the liver findings, especially the shift in Kupffer cells and binucleated hepatocytes, persist in longer studies or correlate with functional biomarkers beyond morphology. (frontiersin.org)